- Home
- YCBD vs BIAF Comparison
YCBD vs BIAF Comparison
Compare YCBD & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- BIAF
- Stock Information
- Founded
- YCBD 2015
- BIAF 2014
- Country
- YCBD United States
- BIAF United States
- Employees
- YCBD N/A
- BIAF N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- YCBD Health Care
- BIAF Health Care
- Exchange
- YCBD Nasdaq
- BIAF Nasdaq
- Market Cap
- YCBD 7.8M
- BIAF 7.6M
- IPO Year
- YCBD N/A
- BIAF 2022
- Fundamental
- Price
- YCBD $1.49
- BIAF $2.96
- Analyst Decision
- YCBD Strong Buy
- BIAF Hold
- Analyst Count
- YCBD 1
- BIAF 1
- Target Price
- YCBD $2.00
- BIAF N/A
- AVG Volume (30 Days)
- YCBD 11.0M
- BIAF 7.7M
- Earning Date
- YCBD 08-14-2025
- BIAF 11-13-2025
- Dividend Yield
- YCBD N/A
- BIAF N/A
- EPS Growth
- YCBD N/A
- BIAF N/A
- EPS
- YCBD N/A
- BIAF N/A
- Revenue
- YCBD $19,026,064.00
- BIAF $7,681,059.00
- Revenue This Year
- YCBD $0.37
- BIAF N/A
- Revenue Next Year
- YCBD $4.95
- BIAF $20.04
- P/E Ratio
- YCBD N/A
- BIAF N/A
- Revenue Growth
- YCBD N/A
- BIAF 4.99
- 52 Week Low
- YCBD $0.59
- BIAF $2.34
- 52 Week High
- YCBD $6.54
- BIAF $67.12
- Technical
- Relative Strength Index (RSI)
- YCBD 72.63
- BIAF 50.36
- Support Level
- YCBD $0.60
- BIAF $2.36
- Resistance Level
- YCBD $1.94
- BIAF $3.65
- Average True Range (ATR)
- YCBD 0.23
- BIAF 0.63
- MACD
- YCBD 0.07
- BIAF -0.28
- Stochastic Oscillator
- YCBD 64.18
- BIAF 12.58
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.